LSPR SEC-arkivering - Larkspur Health Acquisition Corp - Class A- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1859007

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Larkspur Health Acquisition Corp - Class A

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 13, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA T
March 31, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA THERAP
March 31, 2026	EX-19.1	ZYVERSA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Approved by the Board of Directors on December 12, 2022 Exhibit 19.1 ZYVERSA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Approved by the Board of Directors on December 12, 2022 Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) are being provided to you. You should read this Policy, address q
March 5, 2026	EX-4.1	Series A-4 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Exhibit 4.1 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
March 5, 2026	EX-10.2	ZYVERSA THERAPEUTICS, INC. CONVERTIBLE PROMISSORY NOTE Exhibit 10.2 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES THAT MAY BE ACQUIRED PURSUANT TO THIS CONVERTIBLE PROMISSORY NOTE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED
March 5, 2026	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2026, between ZyVersa Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi
March 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commi
December 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commis
November 19, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVER
November 19, 2025	EX-99.1	ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results Exhibit 99.1 ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results ● ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases. ● The lead indication for VAR 200 is
November 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commi
November 14, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-37392 CUSIP NUMBER 03763A207 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr
October 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commis
October 6, 2025	25-NSE	25-NSE X0203 0001354457 Nasdaq Stock Market LLC 0001859007 ZyVersa Therapeutics, Inc. 001-41184 2200 N. Commerce Parkway, Suite 208 Weston FL FLORIDA 33326 (754) 231-1688 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2025-10-06
October 6, 2025	EX-99.25	EX-99.25 Delisting Determination, The Nasdaq Stock Market, LLC, September 18, 2025, ZyVersa Therapeutics, Inc.
September 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Comm
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA TH
August 5, 2025	CORRESP	ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 August 5, 2025 ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 August 5, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 SEC File No. 333-288470 Request for Acceleration To whom it may concern: Pursuant to
August 1, 2025	S-1/A	As filed with the Securities and Exchange Commission on August 1, 2025 As filed with the Securities and Exchange Commission on August 1, 2025 Registration No.
August 1, 2025	CORRESP	* * * * August 1, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 30, 2025	LETTER	LETTER July 30, 2025 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed July 18, 2025 File No. 333-288470 Dear Stephen C. Glover: We have reviewed your amended registration statement and have the following comment. Please respond to this letter
July 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commissio
July 18, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1/A (Form Type) 333-288470 ZyVersa Therapeutics, Inc.
July 18, 2025	S-1/A	As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No.
July 16, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commissio
July 9, 2025	EX-10.1	Inducement Letter, dated July 8, 2025 (incorporated by reference to Exhibit 10.1 to the Company Current Report on Form 8-K, filed with the SEC on July 9, 2025). Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 July 8, 2025 To the Holders of Series A-2 Warrants and Series A-3 Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holders: ZYVERSA THERAPEUTICS, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the oppo
July 9, 2025	EX-4.1	Form of Series A-4 Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 9, 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 9, 2025	EX-10.2	Financial Advisory Agreement, dated July 8, 2025 (incorporated by reference to Exhibit 10.2 to the Company Current Report on Form 8-K, filed with the SEC on July 9, 2025). Exhibit 10.2 CONFIDENTIAL July 8, 2025 ZyVersa Therapeutics, Inc. Attention: Stephen C. Glover 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by ZyVersa Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
July 9, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 ZyVersa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commission
July 2, 2025	S-1	As filed with the Securities and Exchange Commission on July 1, 2025 As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.
July 2, 2025	EX-10.35	Form of Equity Purchase Agreement. Exhibit 10.35 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of June, 2025 the “Execution Date”), by and between ZyVersa Therapeutics, Inc, a Delaware corporation (the “Company”), and Williamsburg Venture Holdings, LLC, a Nevada limited liability company (the “Investor”). RECITALS WHEREAS, the parties desire that, upon the terms and subject to the co
July 2, 2025	EX-10.36	Form of Registration Rights Agreement. Exhibit 10.36 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June , 2025 (the “Execution Date”), is entered into by and between ZyVersa Therapeutics Inc., a Delaware corporation (the “Company”), and Williamsburg Venture Holdings, LLC, a Nevada limited liability company (together with its permitted assigns, the “Buyer”). Capitalized ter
July 2, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
June 25, 2025	EX-99.1	ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator Exhibit 99.1 ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux MediatorTM VAR 200 Weston, FL (June 25, 2025) – ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of pati
June 25, 2025	EX-10.2	Form of Registration Rights Agreement, dated June 24, 2025, by and between ZyVersa Therapeutics, Inc. and Williamsburg Venture Holdings, LLC Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June , 2025 (the “Execution Date”), is entered into by and between ZyVersa Therapeutics Inc., a Delaware corporation (the “Company”), and Williamsburg Venture Holdings, LLC, a Nevada limited liability company (together with its permitted assigns, the “Buyer”). Capitalized term
June 25, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commissio
June 25, 2025	EX-10.1	Form of Equity Purchase Agreement, dated June 24, 2025, by and between ZyVersa Therapeutics, Inc. and Williamsburg Venture Holdings, LLC Exhibit 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of June, 2025 the “Execution Date”), by and between ZyVersa Therapeutics, Inc, a Delaware corporation (the “Company”), and Williamsburg Venture Holdings, LLC, a Nevada limited liability company (the “Investor”). RECITALS WHEREAS, the parties desire that, upon the terms and subject to the con
June 12, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 ZYVERSA THERAPEUTICS, INC.
June 12, 2025	EX-10.1	Amended and Restated ZyVersa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN (as amended and restated on June 11, 2025) 1. Establishment and Purpose 1.1 The purpose of the ZyVersa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship
May 30, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commission
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA T
April 17, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP
April 17, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
April 17, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 8, 2025	LETTER	LETTER April 8, 2025 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed April 4, 2025 File No. 333-286396 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 reg
April 8, 2025	CORRESP	ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 April 8, 2025 ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 April 8, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-286396) (the “Registration Statement”) Ladies and Gentl
April 7, 2025	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction of incorporation) (Commissio
April 7, 2025	EX-16.1	Letter dated April 7, 2025 from Marcum LLP to the U.S. Securities and Exchange Commission (incorporated by reference to Exhibit 16.1 to the Company’s Form 8-K, filed with the SEC on April 7, 2025). Exhibit 16.1
April 7, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive
April 4, 2025	S-3	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZyVersa Therapeutics, Inc.
March 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP
March 27, 2025	EX-19.1	Insider Trading Policies and Procedures. Exhibit 19.1 ZYVERSA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Approved by the Board of Directors on December 12, 2022 Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) are being provided to you. You should read this Policy, address q
March 7, 2025	EX-10.1	Form of Securities Purchase Agreement, dated March 5, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 7, 2025). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 5, 2025, between ZyVersa Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
March 7, 2025	EX-10.2	Placement Agency Agreement, dated March 5, 2025, between the Company and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on March 7, 2025). Exhibit 10.2 March 5, 2025 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the
March 7, 2025	EX-4.3	Form of Amendment to Common Share Purchase Warrant, dated March 5, 2025 (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K, filed with the SEC on March 7, 2025). Exhibit 4.3 AMENDMENT TO COMMON Share PURCHASE WARRANT This AMENDMENT TO COMMON SHARE PURCHASE WARRANT (this “Amendment”) is entered into as of March 5, 2025, by and between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”). WHEREAS, the Holder is the holder of Common Share Purchase Warrants, issued by the Company on November
March 7, 2025	EX-4.1	Form of Pre-Funded Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 7, 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 7, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Submission of Matters to a Vote of Security Holders, Shareholder Director Nominations, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction (Commission (IRS employer of
March 7, 2025	EX-4.2	Form of Series A-3 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed with the SEC on March 7, 2025). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
January 24, 2025	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ZyVersa Therapeutics, Inc.
January 24, 2025	S-8	As filed with the Securities and Exchange Commission on January 24, 2025 As filed with the Securities and Exchange Commission on January 24, 2025 Registration No.
January 17, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
December 30, 2024	424B3	1,637,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-283993 PROSPECTUS 1,637,000 Shares of Common Stock This prospectus relates to the offer and resale of up to an aggregate of 1,637,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) of ZyVersa Therapeutics, Inc. (the “Company,” “we,” “our” or “us”), held by the selling stockholder listed in this prospectus or its permitted tran
December 26, 2024	CORRESP	ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 December 23, 2024 ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 December 23, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-283993) (the “Registration Statement”) Ladies and G
December 23, 2024	LETTER	LETTER December 23, 2024 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed December 20, 2024 File No. 333-283993 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
December 20, 2024	S-3	As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No.
December 20, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZyVersa Therapeutics, Inc.
December 20, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVER
November 14, 2024	EX-99.1	ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update Exhibit 99.1 ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update KEY BUSINESS HIGHLIGHTS ● Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. ● New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development o
November 14, 2024	SC 13G/A	ZVSA / ZyVersa Therapeutics, Inc. / Anson Funds Management LP - SC 13G/A Passive Investment SC 13G/A 1 d886582dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) ZYVERSA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 98987D300 (
November 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ZYVERSA THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction (Commission (IRS employe
November 6, 2024	EX-10.2	Financial Advisory Agreement, dated November 6, 2024 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on November 6, 2024). Exhibit 10.2 CONFIDENTIAL November 5, 2024 ZyVersa Therapeutics, Inc. Attention: Stephen C. Glover 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by ZyVersa Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Comp
November 6, 2024	EX-10.1	Inducement Letter, dated November 5, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 6, 2024). Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 November 5, 2024 To the Holders of December 2023 Common Stock Purchase Warrants and August 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: ZYVERSA THERAPEUTICS, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to yo
November 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 ZYVERSA THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction (Commission (IRS employer
November 6, 2024	EX-4.1	Form of Series A-2 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 6, 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2024	EX-10.1	Amended and Restated ZyVersa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN (as amended and restated on October 29, 2024) 1. Establishment and Purpose 1.1 The purpose of the ZyVersa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietors
October 30, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 ZYVERSA THERAPEUTICS, INC.
September 16, 2024	8-K	8-K, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 ZYVERSA THERAPEUTICS, INC.
September 16, 2024	424B5	424B5 424B5 1 form424b5.htm
September 16, 2024	EX-1.1	Sales Agreement dated September 16, 2024 by and between Zyversa Therapeutics, Inc., and A.G.P./Alliance Global Partners
September 10, 2024	424B3	Common Stock Preferred Stock Debt Securities Purchase Contracts Subscription Rights Filed pursuant to Rule 424(b)(3) File No. 333-281914 PROSPECTUS $100,000,000 Common Stock Preferred Stock Debt Securities Warrants Purchase Contracts Units Subscription Rights From time to time, we may offer and sell up to an aggregate amount of $100,000,000 of any combination of the securities described in this prospectus, either individually or in combination with other securities, in one or mor
September 10, 2024	424B3	478,600 Shares of Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-281913 PROSPECTUS 478,600 Shares of Common Stock This prospectus relates to the offer and resale of up to an aggregate of 478,600 shares of common stock, par value $0.0001 per share (the “Common Stock”) of ZyVersa Therapeutics, Inc. (the “Company,” “we,” “our” or “us”), held by the selling stockholder listed in this prospectus or its permitted transfer
September 9, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
September 9, 2024	CORRESP	ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 September 9, 2024 ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 September 9, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-281914) (the “Registration Statement”) Ladies and G
September 9, 2024	LETTER	LETTER September 9, 2024 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed September 3, 2024 File No. 333-281913 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
September 9, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP
September 9, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
September 9, 2024	LETTER	LETTER September 9, 2024 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed September 3, 2024 File No. 333-281914 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
September 9, 2024	CORRESP	ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 September 9, 2024 ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 September 9, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-281913) (the “Registration Statement”) Ladies and G
September 3, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZYVERSA THERAPEUTICS, INC.
September 3, 2024	S-3	As filed with the Securities and Exchange Commission on September 3, 2024 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No.
September 3, 2024	S-3	As filed with the Securities and Exchange Commission on September 3, 2024 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No.
September 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZyVersa Therapeutics, Inc.
August 30, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA TH
August 9, 2024	EX-3.1	Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 10-Q filed with the SEC on August 9, 2024). Exhibit 3.1
August 1, 2024	EX-10.1	Inducement Letter, dated August 1, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 1, 2024). Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 August 1, 2024 To the Holder of December 2023 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: ZYVERSA THERAPEUTICS, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opp
August 1, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41184 86-2685744 (State or other jurisdiction (Commission (IRS employer o
August 1, 2024	EX-10.2	Financial Advisory Agreement, dated August 1, 2024, between the Company and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on August 1, 2024). Exhibit 10.2 CONFIDENTIAL August 1, 2024 ZyVersa Therapeutics, Inc. Attention: Stephen C. Glover 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by ZyVersa Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Compan
August 1, 2024	EX-4.2	Form of Series B-1 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed with the SEC on August 1, 2024). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
August 1, 2024	EX-4.1	Form of Series A-1 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 1, 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 12, 2024	POS AM	Form S-1 As filed with the U.S. Securities and Exchange Commission on July 11, 2024 Registration No. 333-275320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT under the Securities Act of 1933 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-2685744 (State or other jur
May 15, 2024	EX-97.1	Compensation Recovery Policy. Exhibit 97.1 ZYVERSA THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted as of November 21, 2023) 1. Introduction. Zyversa Therapeutics, Inc. (the “Company”) has adopted this Compensation Recovery Policy (the “Policy”), which provides for the recovery of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requ
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41184 ZYVERSA T
May 15, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41
April 25, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 ZYVERSA THERAPEUTICS, INC.
April 25, 2024	EX-3.1	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc., filed with the Delaware Secretary of State on April 25, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 25, 2024). Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZYVERSA THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) ZyVersa Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follow
April 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 ZYVERSA THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 ZYVERSA THERAPEUTICS, INC.
March 27, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
March 25, 2024	EX-4.8	Exhibit 4.8 Exhibit 4.8 DESCRIPTION OF REGISTRANT’S SECURITIES The following is a description of the securities of ZyVersa Therapeutics, Inc. (“us,” “our,” “we” or the “Company”) as set forth in certain provisions of our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Second Amended and Restated Bylaws (the “Bylaws”), Series A Certificate of Designation, Series B Certificate o
March 25, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP
March 19, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
March 8, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 ZYVERSA THERAPEUTICS, INC.
March 8, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 ZYVERSA THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 ZYVERSA THERAPEUTICS, INC.
February 14, 2024	SC 13G	ZVSA / ZyVersa Therapeutics, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d764036dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) ZYVERSA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 98987D102 (CUSIP
February 14, 2024	SC 13G/A	ZVSA / ZyVersa Therapeutics, Inc. / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g084053sch13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZyVersa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98987D201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the a
February 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d764036dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value, of Zyversa Therapeutics, Inc., a Delaware cor
February 14, 2024	S-8	As filed with the Securities and Exchange Commission on February 14, 2024 As filed with the Securities and Exchange Commission on February 14, 2024 Registration No.
February 14, 2024	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ZyVersa Therapeutics, Inc.
February 9, 2024	SC 13G/A	ZVSA / ZyVersa Therapeutics, Inc. / L1 Capital Global Opportunities Master Fund, Ltd. - SCHEDULE 13G/A Passive Investment SC 13G/A 1 l1cap13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 ZyVersa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 per share (Title of Class of Securities) 98987D 102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
January 19, 2024	SC 13G/A	ZVSA / ZyVersa Therapeutics, Inc. / INCON Co., Ltd. Passive Investment SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 ZYVERSA THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 ZYVERSA THERAPEUTICS, INC.
December 22, 2023	EX-16.1	Letter dated December 22, 2023 from Ernst & Young LLP to the U.S. Securities and Exchange Commission (incorporated by reference to Exhibit 16.1 to the Company’s Form 8-K filed with the SEC on December 22, 2023). Exhibit 16.1 December 22, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated December 22, 2023, of ZyVersa Therapeutics, Inc. and are in agreement with the statements contained in the third paragraph on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
December 11, 2023	EX-4.2	Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed with the SEC on December 11, 2023). Exhibit 4.2 Series A COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Issue Date: [December ], 2023 THIS Series A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after
December 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ZYVERSA THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ZYVERSA THERAPEUTICS, INC.
December 11, 2023	EX-99.1	ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering Exhibit 99.1 ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today the pricing of a
December 11, 2023	EX-4.3	Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K filed with the SEC on December 11, 2023). Exhibit 4.3 Series B COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Issue Date: [December ], 2023 THIS Series B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after
December 11, 2023	EX-10.1	Form of Securities Purchase Agreement, dated as of December 6, 2023, between the Company and each purchaser named in the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 6, 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi
December 11, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on December 11, 2023). Exhibit 4.1 Pre-Funded WARRANT To purchase Shares of Common Stock ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,
December 11, 2023	EX-10.2	Placement Agency Agreement, dated as of December 6, 2023, between the Company and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2023). Exhibit 10.2 December 6, 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (t
December 8, 2023	424B4	400,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,600,000 Shares of Common Stock Series A Common Warrants to purchase up to 4,000,000 Shares of Common Stock Series B Common Warrants to purchase up to 4,000,000 Shares of Common St PROSPECTUS  Filed Pursuant to Rule 424(b)(4) Registration No. 333-275320 400,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,600,000 Shares of Common Stock Series A Common Warrants to purchase up to 4,000,000 Shares of Common Stock Series B Common Warrants to purchase up to 4,000,000 Shares of Common Stock 8,000,000 Shares of Common Stock underlying the Common Warrants 3,600,000
December 6, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 December 6, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-275320 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rul
December 6, 2023	S-1/A	As filed with the Securities and Exchange Commission on December 6, 2023 As filed with the Securities and Exchange Commission on December 6, 2023 Registration No.
December 6, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 December 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-275320 (the “Registration Statement”) Dear Ladies and Gentlemen
December 6, 2023	EX-4.16	Form of Series B Common Warrant Exhibit 4.16 Series B COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Issue Date: [December ], 2023 THIS Series B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after
December 6, 2023	EX-10.29	Form of Securities Purchase Agreement Exhibit 10.29 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 6, 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
December 6, 2023	EX-10.30	Form of Placement Agent Agreement Exhibit 10.30 December [], 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware
December 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
December 6, 2023	EX-4.15	Form of Series A Common Warrant Exhibit 4.15 Series A COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Issue Date: [December ], 2023 THIS Series A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after
December 5, 2023	S-1/A	As filed with the Securities and Exchange Commission on December 4, 2023 As filed with the Securities and Exchange Commission on December 4, 2023 Registration No.
November 30, 2023	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 ZYVERSA THERAPEUTICS, INC.
November 30, 2023	EX-3.1	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc., filed with the Delaware Secretary of State on November 30, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 30, 2023). Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZYVERSA THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) ZyVersa Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follow
November 30, 2023	EX-99.1	ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock Exhibit 99.1 ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock WESTON, FL (November 30, 2023) - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet needs, announces that i
November 21, 2023	EX-10.30	Form of Placement Agent Agreement Exhibit 10.30 November [], 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware
November 21, 2023	S-1/A	As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 Registration No.
November 21, 2023	EX-10.31	Form of Lock-Up Agreement Exhibit 10.31 LOCK-UP AGREEMENT November [], 2023 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, New York 10022 Re: ZyVersa Therapeutics, Inc.—Proposed Offering of Securities Ladies and Gentlemen: The undersigned, a holder of common stock, par value $0.0001 per share (“Shares”), or rights to acquire Shares, of ZyVersa Therapeutics, Inc., a company incorporated under the l
November 21, 2023	EX-10.29	Form of Securities Purchase Agreement Exhibit 10.29 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [], 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s
November 21, 2023	EX-4.15	Form of Common Warrant Exhibit 4.15 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Issue Date: [November ], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after [November ], 2023
November 21, 2023	CORRESP	November 21, 2023 November 21, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
November 21, 2023	EX-4.14	Form of Pre-Funded Warrant Exhibit 4.14 Pre-Funded WARRANT To purchase Shares of Common Stock ZYVERSA THERAPEUTICS, INC. Warrant Shares: [●] Initial Exercise Date: [ November ●], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
November 20, 2023	424B3	ZYVERSA THERAPEUTICS, INC. 5,858,714 Shares of Common Stock 723,234 Shares of Common Stock Underlying Series B Preferred Stock 4,878,875 Shares of Common Stock Underlying PIPE Warrants 5,825,358 Shares of Common Stock Underlying Public Warrants 240,2 PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) Registration Number 333-268934 ZYVERSA THERAPEUTICS, INC.
November 17, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ZYVERSA THERAPEUTICS, INC.
November 16, 2023	LETTER	LETTER United States securities and exchange commission logo November 16, 2023 Stephen C.
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA
November 3, 2023	S-1	As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No.
November 3, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
November 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 ZYVERSA THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 ZYVERSA THERAPEUTICS, INC.
October 24, 2023	424B3	ZYVERSA THERAPEUTICS, INC. 5,858,714 Shares of Common Stock 723,234 Shares of Common Stock Underlying Series B Preferred Stock 4,878,875 Shares of Common Stock Underlying PIPE Warrants 5,825,358 Shares of Common Stock Underlying Public Warrants 240,2 PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Number 333-268934 ZYVERSA THERAPEUTICS, INC.
October 17, 2023	S-1/A	As filed with the Securities and Exchange Commission on October 17, 2023 As filed with the Securities and Exchange Commission on October 17, 2023 Registration No.
October 17, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 October 17, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-268934 (the “Registration Statement”) Dear Ladies and Gentlemen
October 5, 2023	S-1/A	As filed with the Securities and Exchange Commission on October 5, 2023 As filed with the Securities and Exchange Commission on October 5, 2023 Registration No.
October 5, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 CALCULATION OF REGISTRATION FEE Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
October 5, 2023	CORRESP	VIA EDGAR VIA EDGAR October 5, 2023 Joshua Gorsky and Laura Crotty Securities and Exchange Commission 100 F Street, N.
September 20, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (AmeNDment NO. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (AmeNDment NO.
September 14, 2023	EX-4.1	Form of Inducement Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report to Form 8-K filed with the SEC on September 14, 2023). Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: Issue Date: September [], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after [], 2023 (the “Ini
September 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ZYVERSA THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ZYVERSA THERAPEUTICS, INC.
September 14, 2023	EX-10.1	Form of Inducement Letter (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 14, 2023). Exhibit 10.1 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 September 13, 2023 To the Holder of July 2023 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: ZYVERSA THERAPEUTICS, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opp
September 13, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
September 13, 2023	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP
September 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
September 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 ZYVERSA THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 ZYVERSA THERAPEUTICS, INC.
September 1, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERA
August 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 ZYVERSA THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 ZYVERSA THERAPEUTICS, INC.
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period
July 26, 2023	EX-4.8_1	Warrant Amendment (incorporated by reference to Exhibit 4.8.1 to the Company’s Post-Effective Amendment No. 1 to Form S-1 Registration Statement, File No. 333-272657, filed with the SEC on July 26, 2023). Exhibit 4.8.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANT This AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of July 26, 2023, by and between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and the holder signatory hereto (the “Holder”). WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant, issued as of April 28, 2023 and a Term
July 26, 2023	POS EX	As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No.
July 26, 2023	EX-10.1	Placement Agency Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 26, 2023). Exhibit 10.1 July 24, 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the
July 26, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 ZYVERSA THERAPEUTICS, INC.
July 26, 2023	424B4	3,256,060 Shares of Common Stock Pre-Funded Warrants to Purchase 9,471,213 Shares of Common Stock Warrants to purchase 12,727,273 Shares of Common Stock 22,198,486 Shares of Common Stock underlying the Warrants and Pre-Funded Warrants Filed Pursuant to Rule 424(b)(4) Registration No. 333-272657 PROSPECTUS 3,256,060 Shares of Common Stock Pre-Funded Warrants to Purchase 9,471,213 Shares of Common Stock Warrants to purchase 12,727,273 Shares of Common Stock 22,198,486 Shares of Common Stock underlying the Warrants and Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 3,256,060 shares of our common stock, pa
July 26, 2023	EX-99.1	ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering Exhibit 99.1 ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering WESTON, FL (July 24, 2023) - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today the pricing of a “reasonable best
July 18, 2023	SC 13G	ZVSA / ZyVersa Therapeutics Inc / L1 Capital Global Opportunities Master Fund, Ltd. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ZyVersa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 98987D 102 (CUSIP Number) June 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f
July 14, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 July 14, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 272657 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our
July 14, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 July 14, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 272657 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rule
July 14, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 July 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-272657 (the “Registration Statement”) Dear Ladies and Gentlemen: P
July 14, 2023	CORRESP	July 14, 2023 July 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 11, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 July 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-272657 (the “Registration Statement”) Dear Ladies and Gentlemen: P
July 11, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 July 11, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-272657 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rule 4
July 11, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 July 11, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 272657 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our
July 11, 2023	CORRESP	July 11, 2023 July 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 7, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 July 7, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 272657 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rule 4
July 7, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 (754) 231-1688 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 (754) 231-1688 July 7, 2023 VIA EDGAR Joshua Gorsky Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 Filed June 15, 2023 File No. 333-272657 (the “Registration Statement”) Dear Mr. Gorsky: ZyVersa Therapeutics, Inc., a Delawar
July 7, 2023	EX-4.11	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.11 to the Company’s Amendment No. 2 to Form S-1 Registration Statement, File No. 333-272657, filed with the SEC on July 7, 2023). Exhibit 4.11 Pre-Funded WARRANT To purchase Shares of Common Stock ZYVERSA THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: July [●], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
July 7, 2023	CORRESP	July 7, 2023 July 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4720 100 F Street, N.
July 7, 2023	EX-4.10	Form of Common Warrant (incorporated by reference to Exhibit 4.10 to the Company’s Amendment No. 2 to Form S-1 Registration Statement, File No. 333-272657, filed with the SEC on July 7, 2023). Exhibit 4.10 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: Issue Date: July [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after July [●], 2023 (the “Ini
July 7, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 7, 2023 As filed with the Securities and Exchange Commission on July 7, 2023 Registration No.
July 7, 2023	EX-10.24	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.24 to the Company’s Registration Statement on Form S-1/A filed with the SEC on July 7, 2023). Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July [●], 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit
July 7, 2023	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 July [●], 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as sole placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the
June 30, 2023	EX-10.24	Form of Securities Purchase Agreement. Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [●], 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
June 30, 2023	EX-4.10	Form of Warrant in connection with this Offering. Exhibit 4.10 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: Issue Date: [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after [●], 2023 (the “Initial Exerc
June 30, 2023	CORRESP	ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 (754) 231-1688 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 (754) 231-1688 June 30, 2023 VIA EDGAR Joshua Gorsky Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 Filed June 15, 2023 File No. 333-272657 (the “Registration Statement”) Dear Mr. Gorsky: ZyVersa Therapeutics, Inc., a Delawa
June 30, 2023	S-1/A	As filed with the Securities and Exchange Commission on June 30, 2023 As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.
June 30, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
June 30, 2023	EX-4.11	Form of Pre-Funded Warrant in connection with this Offering. Exhibit 4.11 Pre-Funded WARRANT To purchase Shares of Common Stock ZYVERSA THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: [●], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at
June 30, 2023	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 [●], 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as lead placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the “Comp
June 28, 2023	LETTER	LETTER United States securities and exchange commission logo June 28, 2023 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 Filed June 15, 2023 File No. 333-272657 Dear Stephen C. Glover: We have limited our review of your registration statement to those issues we hav
June 15, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ZyVersa Therapeutics, Inc.
June 15, 2023	S-1	Power of Attorney (included on the signature page of this Registration Statement) As filed with the Securities and Exchange Commission on June 14, 2023 Registration No.
June 12, 2023	424B3	11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-269442 Prospectus Supplement No. 4 Dated June 9, 2023 (To Prospectus Dated April 26, 2023) 11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants This Prospectus Supplement No. 4 (this “Prospectus Supplement”) supplements the prospectus of ZyVersa
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 ZYVERSA THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 ZYVERSA THERAPEUTICS, INC.
May 19, 2023	424B3	11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-269442 Prospectus Supplement No. 3 Dated May 19, 2023 (To Prospectus Dated April 26, 2023) 11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants This Prospectus Supplement No. 3 (this “Prospectus Supplement”) supplements the prospectus of ZyVersa
May 19, 2023	EX-FILING FEES	Calculation of filing fee table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ZyVersa Therapeutics, Inc.
May 19, 2023	S-8	As filed with the Securities and Exchange Commission on May 19, 2023 As filed with the Securities and Exchange Commission on May 19, 2023 Registration No.
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 ZYVERSA THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 ZYVERSA THERAPEUTICS, INC.
May 19, 2023	EX-99.1	ZyVersa Therapeutics Announces Changes to ZyVersa Board of Directors Exhibit 99.1 ZyVersa Therapeutics Announces Changes to ZyVersa Board of Directors Weston, FL (May 19, 2023) – ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that two members of the Board of Directors have steppe
May 15, 2023	EX-99.1	ZYVERSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS EX-99.1 2 ex99-1.htm Exhibit 99.1 ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results Key Highlights: ● Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with renal disease ● Announced publication of several peer-reviewed journal articles supporting A
May 15, 2023	424B3	11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-269442 Prospectus Supplement No. 2 Dated May 12, 2023 (To Prospectus Dated April 26, 2023) 11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants This Prospectus Supplement No. 2 (this “Prospectus Supplement”) supplements the prospectus of ZyVersa
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZYVERSA THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZYVERSA THERAPEUTICS, INC.
May 12, 2023	424B3	11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-269442 Prospectus Supplement No. 1 Dated May 12, 2023 (To Prospectus Dated April 26, 2023) 11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants This Prospectus Supplement No. 1 supplements the prospectus of ZyVersa Therapeutics, Inc. (the “Compan
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THER
May 12, 2023	SC 13D/A	ZVSA / ZyVersa Therapeutics Inc / O'Connor Daniel J. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZyVersa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98987D 102 (CUSIP Number) Jared Kelly Lowenstein Sandler LLP One Lowenstein Drive Roseland, NJ 07068 (212) 419-5974 (Name, Address and Te
May 12, 2023	SC 13D/A	ZVSA / ZyVersa Therapeutics Inc / Glover Stephen C. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZyVersa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98987D 102 (CUSIP Number) Jared Kelly Lowenstein Sandler LLP One Lowenstein Drive Roseland, NJ 07068 (212) 419-5974 (Name, Address and Te
May 3, 2023	SC 13G	ZVSA / ZyVersa Therapeutics Inc / Ionic Ventures, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zyversa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98987D102 (CUSIP Number) April 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
April 28, 2023	POS EX	As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No.
April 28, 2023	424B4	11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants Filed Pursuant to Rule 424(b)(4) Registration No. 333-269442 PROSPECTUS 11,015,500 Shares of Common Stock Warrants to Purchase up to 11,015,500 Shares of Common Stock 11,015,500 Shares of Common Stock underlying the Warrants We are offering on a “reasonable best efforts” basis 11,015,500 shares of our common stock, par value $0.0001 per share (“Common Stock”) and warrants to purchase 11,015,500 sh
April 25, 2023	CORRESP	April 25, 2023 April 25, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
April 25, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 April 25, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 269442 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to ou
April 24, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 21, 2023 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No.
April 24, 2023	CORRESP	April 24, 2023 CORRESP 1 filename1.htm April 24, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Laura Crotty Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-269442 Acceleration Request Requested Date: April 26, 2023 Reques
April 24, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 April 24, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 269442 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rule
April 21, 2023	CORRESP	A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 A.G.P./ALLIANCE GLOBAL PARTNERS 590 Madison Avenue 28th Floor New York, New York 10022 April 21, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333- 269442 (the “Registration Statement”) Ladies and Gentlemen: In accordance with Rule
April 21, 2023	LETTER	LETTER United States securities and exchange commission logo April 21, 2023 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed April 12, 2023 File No. 333-268934 Dear Stephen C. Glover: We have reviewed your amended registration statement and ha
April 21, 2023	CORRESP	April 21, 2023 April 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4720 100 F Street, N.
April 18, 2023	EX-4.9	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.9 to the Company’s Registration Statement filed with the SEC on April 24, 2023). Exhibit 4.9 Pre-Funded WARRANT To purchase Shares of Common Stock ZYVERSA THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: April [●], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
April 18, 2023	EX-4.8	Form of Warrant (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement filed with the SEC on April 24, 2023). Exhibit 4.8 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC. Warrant Shares: Issue Date: April [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after April [●], 2023 (the “In
April 18, 2023	EX-1.1	Form of Placement Agency Agreement (incorporated by reference to Exhibit 1.1 to Company’s Registration Statement on Form S-1 filed with the SEC on April 24, 2023) Exhibit 1.1 April [●], 2023 Attn: Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Dear Mr. Glover: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as lead placement agent (the “Placement Agent”), and ZyVersa Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the
April 18, 2023	EX-10.23	Form of Escrow Agreement (incorporated by reference to Exhibit 10.23 to Company’s Registration Statement on Form S-1 filed with the SEC on April 24, 2023) Exhibit 10.23 ESCROW AGREEMENT This ESCROW AGREEMENT (this “Agreement”) made as of [●], 2023, by and among ZyVersa Therapeutics, Inc. (the “Issuer”), whose address and other information appears on the Information Sheet (as defined herein) attached to this Agreement, and Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, NY 10004 (the “Escrow Agent”). WITNESSETH: WHER
April 18, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 17, 2023 As filed with the Securities and Exchange Commission on April 17, 2023 Registration No.
April 18, 2023	EX-10.22	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.22 to Company’s Registration Statement on Form S-1 filed with the SEC on April 24, 2023) Exhibit 10.22 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April [●], 2023, between ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi
April 17, 2023	CORRESP	Jared Kelly Jared Kelly 1251 6th Avenue, 17th Floor New York, NY 10020 T: (212) 419-5974 F: (212) 262-7402 E: JKelly@lowenstein.
April 14, 2023	LETTER	LETTER United States securities and exchange commission logo April 14, 2023 Peter Wolfe Chief Financial Officer ZyVersa Therapeutics, Inc.
April 12, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 11, 2023 S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on April 11, 2023 Registration No. 333-268934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ZYVERSA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 86-2685744 (State or other j
April 11, 2023	CORRESP	Jared Kelly Jared Kelly 1251 6th Avenue, 17th Floor New York, NY 10020 T: (212) 419-5974 F: (212) 262-7402 E: JKelly@lowenstein.
April 5, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 4, 2023 As filed with the Securities and Exchange Commission on April 4, 2023 Registration No.
April 3, 2023	8-K	Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 ZYVERSA THERAPEUTICS, INC.
April 3, 2023	EX-99.1	ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Exhibit 99.1 ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results April 3, 2023 Key Highlights: ● Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol “ZVSA” ● Planning underway with nephrologists for an investigator-initiated clinical trial in focal segmental g
March 31, 2023	EX-4.8	Description of the Company’s Securities. Exhibit 4.8 DESCRIPTION OF REGISTRANT’S SECURITIES The following is a description of the securities of ZyVersa Therapeutics, Inc. (“us,” “our,” “we” or the “Company”) as set forth in certain provisions of our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Second Amended and Restated Bylaws (the “Bylaws”), Series A Certificate of Designation, Series B Certificate o
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41184 ZYVERSA THERAP

LSPR / Larkspur Health Acquisition Corp - Class A - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?